The Study of Cerumen Hepatitis B Infection in Chronic Hepatitis B Patients by Real-Time PCR

Document Type : Original


1 Microbiology Research Center lab, Ilam University of Medical Sciences, Ilam, Iran

2 Faculty of Medicine , Ilam University of Medical Sciences, Ilam, Iran

3 Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran

4 Faculty of Medicine , Guilan University of Medical Sciences, Guilan, Iran


The hepatitis B is a viral infection that causes a big problem globally. About 2 billion people worldwide are infected and there are now about 400 million HBV-DNA carriers around the world. HBV infection is the ninth cause of death worldwide and infects about 350 million new cases each year in the world. HBV-DNA can be spotted in different body secretions and fluids, including serum, saliva, tears, urine, amniotic fluid index, and cerumen isolated.
Materials and Methods:
This is a case - control study on the population of 140 participants (70 patients with chronic hepatitis B as cases and 70 healthy volunteers community as a control). The presence of HBV-DNA in their serum and ears cerumen using qualitative PCR and quantitative molecular detection Real-Time PCR (BioRad-CFX system) was determined.  
Copy of serum HBV were detected in 98.5 % of case group and 7 % of healthy population (control group). In case group, 61 patients (87.2%) had HBV-DNA in their cerumens and 5control subjects (about 7 %)  were positive for HBV-DNA in their cerumens. All patients group and two subject (2.8%) of control group, were positive in HBsAg test.
Average HB virus genome load in cerumen and serum of chronic HBV patients (group) were 8.98×106 and 3.60×108 copies per ml of the sample respectively.
Like other body secretions, Ear cerumen is constantly produced and is subject to a pathogen such as HBV infection. The possiblity of disease transmission seems unlikely through Cerumen, however considering the average copy of HBV genome in the cerumen, no doubt, it can be claimed that there is a potential transmission risk of HBV infection.


  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
  2. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S,Michel ML. Immunogencity of a hepatitis B DNA vaccine  administered to chronic HBV carries. Vaccine 2006; 24: 4482-9.
  3. Kalcioglu MT, Durmza R, Ozturan O, Bajindir Y, Direkel S. Does cerumen have a risk for transmission of hepatitis B? Laryngoscope 2004; 114: 577-80.
  4. Gohi EY, Son Bo Y, Kong SK, Chon KM, Cho KS. Analysis of the hepatitis B virus in the cerumen and otorrhea of chronic HBV-infected patients. Otol Neurotol 2008; 29: 929-32.
  5. Taber E, Gerety RJ. Possible role of immune response to hepatitis B core antigen in protection against hepatitis B infection. Lancet 1984; 1: 172.
  6. Lemon SM, Thoimas Dl. Vaccine to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204.
  7. Robins WS. Hepatitis B virus and hepatitis D virus. In: Mandell, Bennett JE, Dolin R. (editors). Mandell, Douglas and Benntts principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000: 1652-84.
  8. Eijk AA, Niesters HG, Gotz HM, Janssen HL, Schalm SW, Osterhaus AD, et al. Paired measurements of quantitive hepatitis B virus DNA in Saliva and serum of chronic hepatitis  B patitents: Implication for saliva as infectious agent. J Clin Virol 2004; 29: 92-4.
  9. Oon CJ, Chen WN, Goh KT, Mesenas S, Ng HS, Chaing G, et al. Molecular characterization of hepatitis B virus surface antigen mutants in Singapore patients with hepatocellular carcinoma and hepatitis B carries negative for HBsAg but positive for Anti-HBc. J  Gastroentrol Hepatol 2002; 17: 5491-6.
  10. Shi YH, Shi Ch. Molecular characteristic and of chronic hepatitis B virus infection. World J Gasetrol 2009; 15: 3099-105.
  11. Lau STY, Everhart  J, Kliner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology 1997; 113: 1660-7.
  12. Gish RG, Gadano AC. Chronic hepatitis B, current epidemiology in the Americas and implification for managment. J Viral Hepat 2006; 13: 187-9.
  13. Alavian SM, Hajarizaddeh B, Ahmadzad AS, Kabiri A, Bagheri Lan-Karani k. Hepatitis B virus infection in Iran: A systematic review.  Hepatitis 2008; 8(4): 281-94.
  14. Aki AB, Inou EK, Tanaka T, Kato J, Kajijama N, Kawaguchi R, et al. Quantitation of hepatitis B virus genomic DNA by real time detection PCR. J Microbiol 1999; 2899-903.
  15. Hatzakis A, Magiorkinis E, Haida C. HBV virological assessment. J Hepatol 2006; 44: 557-71.
  16. Biswas RE, Tabor E, Hsia CC, Wrigth DJ, Laycock ME, Fiebig EW, et al. Comparative sensitivity of HBV NATs and HBsAg assay for detection of acute HBV infection. Transfusion 2003; 43: 788-98.
  17. Ulrich PP, Bath RA, Seto B, Mack D, Sininsky J, Vyas GN .Enzymatic amplification of hepatitis B virus in serum compared with infectivity testing in chimpanzees. J Infect Dis 1989; 160: 37-43.
  18. Hendrisk DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, et al. Quantitation of HBV DNA in human serum using branched DNA signal amplification assay. AMJ Clin Pathol 1995; 104: 537-46.
  19. Ho SK, Chan TM. An overview of assay for serum HBV DNA. Clin Lab 2000; 46: 609-14.
  20. Sum SM, Wong DK, Yuen MF, Yuan HJ, Yu J, Lai CH, et al. Real time PCR assay using molecular  beaconfor quantitation of hepatitis B virus DNA. J Clin Microbiol 2004; 42(8): 3438-40.
  1. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastrointrol 2004; 127(5supp1): 56-61.
  1. Chemin I, Trepo C. Clinical impact of occult HBV. J Clinical Virol 2005; 34(1): 15-21.